Jump to content
  • Sign Up
0
Scott Adams

ImmusanT, Developing Celiac Disease Treatments, Closes $20M Series A - Xconomy

Rate this topic

Recommended Posts

6.jpg

Mass High Tech

ImmusanT, Developing Celiac Disease Treatments, Closes $20M Series A

Xconomy

Cambridge, MA-based ImmusanT, a new biotech working on therapies targeting celiac disease, announced today that it has wrapped up $20 million in Series A financing from New York-based Vatera Healthcare Partners. The money will go to development of ...

ImmusanT gets $20M Series A shot for celiac vaccine Mass High Tech

ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic ... PR Newswire (press release)

Cambridge, MA startup snags $20M for therapeutic vaccine program FierceBiotech

Fortune (blog)

all 12 news articles »

View the full article

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
0

×